Modified IFN-Bevacizumab Regimen in Renal CancerModified IFN-Bevacizumab Regimen in Renal Cancer

For first-line treatment of metastatic renal cell carcinoma (mRCC), low-dose interferon-alpha (IFN) works as well as high-dose IFN when combined with bevacizumab and is better tolerated. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news